FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines
The Food and Drug Administration’s decision, made public on Feb. 10, 2026, to not review an application to approve Moderna’s...
Read more














